Last reviewed · How we verify
Mitoxantrone, Cytarabine
Mitoxantrone and cytarabine are chemotherapy agents that work together to inhibit DNA synthesis and induce apoptosis in leukemic cells.
Mitoxantrone and cytarabine are chemotherapy agents that work together to inhibit DNA synthesis and induce apoptosis in leukemic cells. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL).
At a glance
| Generic name | Mitoxantrone, Cytarabine |
|---|---|
| Sponsor | The First Hospital of Jilin University |
| Drug class | Chemotherapy combination (topoisomerase II inhibitor + nucleoside analog) |
| Target | Topoisomerase II (mitoxantrone); DNA polymerase (cytarabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Mitoxantrone is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA repair, while cytarabine is a nucleoside analog that inhibits DNA polymerase and gets incorporated into DNA, causing chain termination. Together, they create a synergistic cytotoxic effect against rapidly dividing hematologic malignancies.
Approved indications
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Mucositis
- Cardiotoxicity (mitoxantrone-related)
- Infection
- Hepatotoxicity
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML (NA)
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML (PHASE3)
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML (PHASE2)
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. (PHASE3)
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (PHASE1)
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mitoxantrone, Cytarabine CI brief — competitive landscape report
- Mitoxantrone, Cytarabine updates RSS · CI watch RSS
- The First Hospital of Jilin University portfolio CI